CULLINAN THERAPEUTICS INC
CGEMNASDAQTrading Snapshot
- Day Range
- $19.38 – $19.91
- 52-Week Range
- $5.68 – $19.43
- Volume
- $3.68B
- Avg Volume
- $2.77B
- Shares Outstanding
- 61.5M
- Next Earnings
- Sep 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $84M
- Last Q Revenue
- $22M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.41
- Dividend Yield
- —
Why Investors Own CGEM
- ✓High-growth profile — revenue up +53.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 46% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CULLINAN THERAPEUTICS INC
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Cullinan Therapeutics (NASDAQ:CGEM) Shares Jump on Inline Q2 Earnings and Pipeline Milestones
Cullinan's Q2 matches estimates; stock up ~17% on robust pipeline catalysts, with multiple data readouts and FDA-accepted NDA ahead.
Cullinan Therapeutics Q2 EPS $(0.81) Beats $(0.85) Estimate
Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.85) by 4.71 percent. This is a 24.3 percent increase over losses of $(1.07) per share
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $39
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $38 to $39.
Cullinan Therapeutics Announces Positive Feedback From FDA Following End-Of-Phase 1 Meeting For CLN-049, FLT3xCD3 T Cell Engager Being Evaluated In Patients With Acute Myeloid Leukemia
Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan"))), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and